A review of post-marketing safety and surveillance data for oral contraceptives containing norgestimate and ethinyl estradiol.
Lippman
J S
JS
Ortho-McNeil Pharmaceutical, USA.
Shangold
G A
GA
D000293:Adolescent; D000328:Adult; D017677:Age Distribution; D002170:Canada / Q000453:epidemiology; D016022:Case-Control Studies; D003277:Contraceptives, Oral, Combined / Q000009:adverse effects*; D003280:Contraceptives, Oral, Synthetic / Q000009:adverse effects*; D004997:Ethinyl Estradiol / Q000009:adverse effects*; D005260:Female; D006801:Humans; D008875:Middle Aged; D009203:Myocardial Infarction / Q000139:chemically induced* / Q000453:epidemiology; D009644:Norgestrel / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D009656:North America / Q000453:epidemiology; D011358:Product Surveillance, Postmarketing / Q000706:statistics & numerical data*; D016032:Randomized Controlled Trials as Topic; D012307:Risk Factors; D013923:Thromboembolism / Q000139:chemically induced* / Q000453:epidemiology; D014481:United States / Q000453:epidemiology
D003277:Contraceptives, Oral, Combined; D003280:Contraceptives, Oral, Synthetic; D009644:Norgestrel; D004997:Ethinyl Estradiol; C017576:norgestimate